Integrated Intervention Engages PLWHIV who Inject Drugs

Share this content:
Increasing the uptake of ART and medication-assisted therapy services combined with standard harm reduction services in PWID who have HIV will probably reduce mortality in HIV-infected PWID.
Increasing the uptake of ART and medication-assisted therapy services combined with standard harm reduction services in PWID who have HIV will probably reduce mortality in HIV-infected PWID.

A flexible, scalable intervention increases antiretroviral therapy (ART) and medication-assisted treatment use while reducing mortality in people who inject drugs (PWID), according to study results published in The Lancet.

The burden of HIV incidence is disproportionately high in the PWID population, especially in southeast and central Asia and Eastern Europe. This HIV epidemic in PWID persists due to low rates of HIV testing, insufficient access to and use of HIV prevention services and HIV care, poor access to treatment for substance misuse and harm-reduction services, and persistent social barriers such as stigma and punitive legal systems. Enhancing HIV care engagement could increase uptake of ART, viral suppression, and survival, while also possibly reducing transmission to injection partners who are not HIV-infected. Therefore, this multi-site, randomized study (ClinicalTrials.gov identifier: NCT02935296) assessed the feasibility of a future controlled trial based on the incidence of HIV, enrollment, retention, and uptake of the intervention, as well as the efficacy of an integrated and flexible intervention on ART use, viral suppression, and medication-assisted treatment use.

This study was conducted in Kyiv, Ukraine; Thai Nguyen, Vietnam; and Jakarta, Indonesia. PWID infected with HIV (n=503) and non-infected injection partners (n=806) who age 18 to 60 were included. PWID with >1000 HIV viral copies/ml were randomly assigned to intervention (25%) or standard of care (75%). The intervention comprised systems navigation, psychosocial counselling, and ART at any CD4 count. Participants were followed for up to 12 to 24 months.

At week 52, 86% of intervention participants and 80% of partners were retained, and self-reported ART use was higher in participants in the intervention group than participants in the standard of care group (probability ratio [PR] 1.7; 95% CI, 1.4-1.9). Viral suppression was also higher in the intervention group compared with the standard of care group (PR 1.7; 95% CI, 1.3-2.2). In addition, at 52 weeks, participants in the intervention group reported more medication-assisted therapy use than participants in the standard of care group (PR 1.7; 95% CI, 1.3-2.2). A total of 7 new HIV infections occurred in the injection partners, all of whom were in the standard of care group.  Mortality was lower in the intervention group than in the standard of care group: 5.6 deaths per 100 person-years in the intervention group vs 12.1 deaths per 100 person-years in the standard of care group. Mortality was also lower in injection partners in the intervention group (0.46 deaths per 100 person-years) compared with the standard of care group (2.6 deaths per 100 person-years).

Researchers noted that these findings indicated integrated intervention, including brief, focused, individualized psychosocial counselling, for PWID infected with HIV could lead to increased ART adherence, medication-assisted therapy use, and viral suppression.

Overall, the study authors concluded that, “Increasing the uptake of ART and [medication-assisted therapy] services combined with standard harm reduction services for PWID who have HIV will probably reduce mortality among HIV-infected PWID, and possibly, among their uninfected injection partners. To reach this population, flexible, innovative, low-cost, scalable programs are needed to support sustained use of ART and [medication-assisted treatement].”

Reference

Miller WC, Hoffman IF, Hanscom BS, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018;392:747-759

You must be a registered member of Infectious Disease Advisor to post a comment.

SIGN UP FOR FREE E-NEWSLETTERS